Director, Hematologic Malignancies & Cellular Therapy

American Society Of Clinical Oncology, Inc.; Bloomington (IL); Presencial; USD 600.000 - 650.000; Jornada completa

Ventajas ofrecidas por este puesto de trabajo

Sign-on bonus

Relocation assistance

CME opportunities

401(k) match

PSLF eligibility

Descripción de la vacante

The American Society Of Clinical Oncology, Inc. is building a brand-new employed hematology/oncology program in a new cancer center.

You will lead a four-physician hematology group within a 25-physician hem/onc program and dedicate 40% protected time to leadership and clinical research. The role focuses on launching cellular therapy, including BMT and CAR-T, with extensive trial access and an optional academic faculty appointment.

Formación

• BE/BC Hematology or Oncology required.
• Background in BMT and cellular therapy; fellowship is a plus, not required.
• Experience with cellular therapy trials preferred.

Responsabilidades

• Lead a group of 4 hematologists within a 25 physician hem/onc program.
• Maintain 40% protected time for leadership and clinical research.
• Launch cellular therapy program including BMT and CAR-T within 2–3 years.
• Focus on malignant hematology with no coagulation program.
• Participate in phase 1–4 trials with access to 500+ trials via national research partnership.
• Coordinate with BMT coordinator, hematology APP and nurse navigator.
• Occasional academic faculty appointment.
• Refer patients; ~80% have an integrated primary care provider.

Conocimientos

Leadership

Clinical trial experience

Cellular therapy knowledge

Educación

BE/BC Hematology or Oncology

Descripción del empleo

The American Society Of Clinical Oncology, Inc. is building a brand-new employed hematology/oncology program in a new cancer center.

You will lead a four-physician hematology group within a 25-physician hem/onc program and dedicate 40% protected time to leadership and clinical research. The role focuses on launching cellular therapy, including BMT and CAR-T, with extensive trial access and an optional academic faculty appointment.